Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
1. A method for improving glycemic control in a patient with type 2 diabetes mellitus comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical combination comprising:
(a) lixisenatide or a pharmaceutically acceptable salt thereof, and
(b) insulin glargine or a pharmaceutically acceptable salt thereof,
wherein the patient's type 2 diabetes mellitus is inadequately controlled after treatment with basal insulin at a dose of about 15 units to about 80 units per day for at least about 3 months.
2. The method of claim 1 , wherein the patient is an adult.
3. The method of claim 1 , wherein the patient has a glycosylated hemoglobin A 1c (HbA 1c ) value of about 7% to about 10% after treatment with basal insulin.
4. The method of claim 1 , wherein the basal insulin is insulin glargine.
5. The method of claim 1 , wherein the pharmaceutical combination comprises a daily dose of about 15 units to about 80 units of insulin glargine.
6. The method of claim 1 , wherein the pharmaceutical combination comprises a daily dose of about 10 μg to about 20 μg of lixisenatide.
7. A method for improving glycemic control in a patient with type 2 diabetes mellitus, the method comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical combination comprising:
(a) lixisenatide or a pharmaceutically acceptable salt thereof, and
(b) insulin glargine or a pharmaceutically acceptable salt thereof,
wherein the patient's type 2 diabetes mellitus is inadequately controlled after treatment with basal insulin at a dose of about 15 units to about 80 units per day and metformin at a dose of at least about 1.0 g per day for at least about 3 months.
8. The method of claim 7 , wherein the basal insulin is insulin glargine.
9. The method of claim 7 , wherein the pharmaceutical combination comprises a daily dose of about 15 units to about 80 units of insulin glargine.
10. The method of claim 7 , wherein the pharmaceutical combination comprises a daily dose of about 10 μg to about 20 μg of lixisenatide.
11. The method of claim 7 , wherein the patient is an adult.
12. The method of claim 7 , wherein the patient has an HbA 1c value of about 7% to about 10% after treatment with basal insulin and metformin.
13. The method of claim 7 , further comprising administering to the patient a therapeutically effective amount of metformin.
14. The method of claim 1 or 7 , wherein the basal insulin is a long-acting basal insulin.